Hoersholm; June 21, 2016 – Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) has been approved for listing on Nasdaq Stockholm First North and has now received formal approval from the marketplace. First day of trading in MPIs shares is Monday June 27th 2016. Last day of trading on Nasdaq Copenhagen First North is Friday June 24th 2016.
Change of Central Securities Depository
Ninety-six (96%) percent of the shareholders have already moved their shares to the Swedish Euroclear and is available in Sweden from the first day of trading. Trading at Nasdaq Stockholm First North requires registration of MPI shares by Euroclear Sweden AB. This means, shareholders wishing to trade their MPI shares need to have them registered at Euroclear Sweden AB.
MPI will – if asked – assist shareholders who still have their MPI-shares in Denmark in moving them to Sweden.
Certified Adviser appointed for trading at Nasdaq Stockholm First North
MPI has appointed Sedermera Fondkommission to be their Certified Adviser. Sedermera Fondkommission will begin their work for MPI as of the first trading day at Nasdaq Stockholm First North.
Medical Prognosis is a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP(TM) technology. MPI’s exceptional opportunity to personalize cancer treatment – begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI’s DRP(TM) tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a large database with over 1,000 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark.
Oncology Venture a spin out from MPI uses the DRP(TM) for drug development.
About MPI’s multiple biomarker called Drug Response Predictor – DRPTM
MPI’s DRPTM is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRPTM has been tested in 37 trials, where 29 trials showed that drug-specific DRPTM Biomarkers could predict which patients responded well to the treatment. The DRPTM platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRPTM method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anti-cancer drug. In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRPTM builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. MicroRNA is used on certain products whereas the messengerRNA is more broadly useable and more validated. The DRPTM platform can be used in all cancer types, and has been patented for more than 60 anti-cancer drugs in the US.
For further information, please contact:
CEO, Peter Buhl Jensen, Adjunct Professor, MD, Ph.d. Ulla Hald Buhl, IR & Communication
E-mail: email@example.com E-mail: firstname.lastname@example.org
Telephone: +45 21 60 89 22 Telephone +45 21 70 10 49
Certified Adviser: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Denmark